Search results
Results from the WOW.Com Content Network
Anthrax vaccines are vaccines to prevent the livestock and human disease anthrax, caused by the bacterium Bacillus anthracis. [1]They have had a prominent place in the history of medicine, from Pasteur's pioneering 19th-century work with cattle (the first effective bacterial vaccine and the second effective vaccine ever) to the controversial late 20th century use of a modern product to protect ...
Anthrax vaccine adsorbed, sold under the brand name Biothrax among others, is a vaccine intended to provide acquired immunity against Bacillus anthracis. [3] [5] [4]Anthrax vaccine adsorbed originated in studies done in the 1950s and was first licensed for use in humans in 1970.
The Anthrax Vaccine Immunization Program (AVIP), is the name of the policy set forth by the U.S. federal government to immunize its military and certain civilian personnel with BioThrax, an anthrax vaccine manufactured by Emergent BioSolutions Inc. It was set up by the Clinton administration.
The vaccine, Cyfendus, has been approved for use following suspected or confirmed exposure to a type of bacteria and has to be administered together with antibacterial drugs. Anthrax is a ...
The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.
Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Bruce Edwards Ivins (/ ˈ aɪ v ɪ n z /; April 22, 1946 – July 29, 2008) [1] was an American microbiologist, vaccinologist, [1] senior biodefense researcher at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, and the person suspected by the FBI of the 2001 anthrax attacks. [2]
BioThrax is the only anthrax vaccine licensed by the FDA. [57] Another company, VaxGen had received an $877.5 million contract to produce an alternative anthrax vaccine that was reported to "cause fewer side effects", require fewer injections, and have faster effectiveness. Following lobbying from Emergent BioSolutions, VaxGen's contract was ...